Skip to content Skip to footer

5 Critical Steps in the TIPS Procedure for Portal Hypertension

Master the TIPS procedure with this evidence-based guide covering patient selection, stent deployment, pressure-gradient endpoints, and complication management for interventional radiology teams.

TIPS Procedure: A Complete Interventional Radiology Protocol for Portal Hypertension

At a glance

  • The TIPS procedure creates a low-resistance shunt between hepatic and portal veins using an ePTFE-covered stent
  • Primary indications include refractory ascites, acute variceal bleeding, and hepatic hydrothorax
  • Target portosystemic pressure gradient is <12 mmHg for optimal clinical outcomes
  • Viatorr stent-grafts achieve 1-year primary patency of 80–90%
  • Hepatic encephalopathy develops in 15–30% of patients after the TIPS procedure and requires proactive management

Introduction to the TIPS procedure

The TIPS procedure remains one of the most technically demanding yet life-saving interventions in modern hepatobiliary interventional radiology. By creating a low-resistance channel between the portal and hepatic venous systems, transjugular intrahepatic portosystemic shunt placement effectively decompresses portal hypertension while avoiding open surgery. This evidence-based guide provides interventional radiologists, radiographers, and hospital administrators with a comprehensive protocol covering patient selection, technical execution, and long-term surveillance after the TIPS procedure.

Clinical context The TIPS procedure is indicated for complications of portal hypertension including refractory ascites, acute variceal hemorrhage, and hepatic hydrothorax. Multidisciplinary coordination between interventional radiology, hepatology, and anesthesia teams is essential for optimal outcomes.

🏥 Optimize Your IR Workflow

Streamline your interventional radiology procedures with integrated consumable solutions designed for complex hepatobiliary cases.

Explore SATMED Health Solutions →

Pathophysiology of portal hypertension

The portal venous system and cirrhosis

Portal hypertension arises from increased resistance to portal blood flow, most commonly secondary to hepatic cirrhosis. The pathophysiology involves both intrahepatic vascular distortion from fibrotic remodeling and splanchnic vasodilation driven by nitric oxide and other vasoactive mediators. As portal pressure rises, collateral pathways develop through the gastroesophageal veins, umbilical system, and retroperitoneal plexus, creating the anatomic substrate for variceal formation and bleeding that may ultimately necessitate the TIPS procedure.

Hemodynamic consequences

The hepatic venous pressure gradient (HVPG) serves as the gold-standard measurement of portal pressure, with values >10 mmHg defining clinically significant portal hypertension. Above this threshold, patients face increased risks of variceal development, ascites formation, and hepatorenal syndrome. The TIPS procedure directly addresses this hemodynamic derangement by shunting portal blood into the systemic venous circulation, thereby reducing the portosystemic gradient and decompressing the splanchnic bed.

Clinical indications and patient selection

Accepted indications for the TIPS procedure

Current guidelines from the American Association for the Study of Liver Diseases (AASLD) and Baveno VII consensus endorse the TIPS procedure for several well-defined clinical scenarios.[1,2] Refractory ascites that persists despite sodium restriction and maximal diuretic therapy represents the most common elective indication. Acute variceal hemorrhage uncontrolled by endoscopic therapy or recurrent bleeding despite band ligation and beta-blockade constitutes an urgent indication. Additional accepted indications include hepatic hydrothorax, Budd-Chiari syndrome, and hepatorenal syndrome as a bridge to transplantation.

Evidence highlight Early TIPS procedure placement within 72 hours of acute variceal bleeding in high-risk patients (Child-Pugh C <14 or Child-Pugh B with active bleeding) significantly improves survival compared to standard pharmacologic and endoscopic therapy.[3]

Relative and absolute contraindications

Absolute contraindications to the TIPS procedure include congestive heart failure, severe pulmonary hypertension, uncontrolled systemic infection, and unrelieved biliary obstruction. Relative contraindications encompass hepatic encephalopathy unresponsive to medical therapy, portal vein thrombosis without recanalization potential, moderate pulmonary hypertension, and hepatocellular carcinoma occupying the proposed tract. The MELD score serves as a critical risk stratification tool; patients with MELD >18–20 or serum bilirubin >4.0 mg/dL face substantially higher 3-month mortality after the TIPS procedure and require careful multidisciplinary deliberation.[4,12]

💉 Precision Hemodynamic Access

SATLine consumables deliver reliable vascular access for portal pressure monitoring and TIPS procedure creation.

Discover SATLine Technology →

Pre-procedural evaluation

Laboratory assessment and MELD scoring

Comprehensive laboratory evaluation before the TIPS procedure includes complete blood count, comprehensive metabolic panel, coagulation profile, and type and screen. The MELD-Na score provides superior prognostic accuracy compared to Child-Pugh classification for predicting post-TIPS mortality. Platelet counts <50,000/μL and INR >1.8 warrant pre-procedural correction with fresh frozen plasma or platelet transfusion. Serum ammonia levels establish baseline encephalopathy risk, while lactulose and rifaximin should be initiated prophylactically in high-risk patients.[16]

Cross-sectional imaging protocols

Before performing the TIPS procedure, contrast-enhanced CT or MRI is mandatory for evaluating portal vein patency, hepatic vein anatomy, spleen size, ascites volume, and the extent of portosystemic collaterals. Imaging should assess for portal vein thrombosis, which may require recanalization or alter the technical approach. The proposed intrahepatic tract should be evaluated for intervening tumors, cysts, or dilated biliary radicals that could increase procedural risk. For patients with suspected cardiac compromise, transthoracic echocardiography evaluates right heart function and pulmonary pressures.[2,9]

Cardiac and pulmonary risk stratification

Because the TIPS procedure acutely increases venous return to the right heart, patients with tricuspid regurgitation, cardiomyopathy, or right heart failure may decompensate hemodynamically. Cardiology consultation and echocardiographic assessment are recommended when clinical suspicion exists. Prophylactic antibiotics with gram-negative and anaerobic coverage should be administered within 60 minutes of skin incision.[8,11]

Step-by-step TIPS procedure technique

Vascular access and hepatic vein cannulation

The TIPS procedure is performed under general anesthesia or deep conscious sedation with continuous cardiopulmonary monitoring. The right internal jugular vein is accessed under ultrasound guidance using a micropuncture set, followed by placement of a 10F vascular sheath. A 5F multipurpose catheter is advanced through the right atrium and inferior vena cava into the right hepatic vein. Free hepatic vein pressure is measured and recorded as the baseline for subsequent gradient calculations.

Portal vein puncture and tract creation

During the TIPS procedure, portal vein localization is achieved using CO2 wedged hepatic venography or intravascular ultrasound (IVUS), with the latter gaining favor for improved safety and reduced contrast load. A Colapinto needle (Rösch-Uchida or Ring transjugular liver access set) is advanced through the hepatic parenchyma toward the right portal vein branch. Successful puncture is confirmed by aspiration of blood and contrast injection demonstrating portal venous anatomy. A 0.035-inch Amplatz wire is advanced into the superior mesenteric or splenic vein.[8,9]

Technical caution During the TIPS procedure, needle passes should be limited to minimize parenchymal injury and capsular perforation risk. If multiple passes fail, consider alternative hepatic vein selection or CT-fluoroscopy guidance. Biplane fluoroscopy significantly improves spatial orientation during portal vein targeting.

Stent deployment and balloon dilation

During the TIPS procedure, the parenchymal tract is predilated with an 8 mm angioplasty balloon, followed by deployment of the covered stent-graft. The stent is positioned with the proximal end in the portal vein and the distal end in the hepatic vein, ensuring complete coverage of the parenchymal tract. Post-deployment balloon dilation to 8–10 mm achieves the desired caliber. A completion portogram confirms stent position, excludes extravasation, and demonstrates antegrade portal flow through the shunt.[8,10]

🧤 Maintain Sterile Field Integrity

SATDrape advanced sterile barrier systems ensure optimal aseptic conditions during the TIPS procedure.

View SATDrape Solutions →

Stent selection and deployment

Covered versus bare-metal stents

Contemporary practice for the TIPS procedure overwhelmingly favors ePTFE-covered stent-grafts over bare-metal stents. The Viatorr endoprosthesis combines a bare-metal portal venous segment with a covered intrahepatic segment, reducing intimal hyperplasia and pseudointimal formation. Covered stents achieve 1-year primary patency of 80–90% compared to 20–30% for bare-metal equivalents, with corresponding improvements in transplant-free survival.[6,22]

Viatorr stent-graft specifications

The Viatorr device is available in diameters of 8 mm and 10 mm with lengths ranging from 5 cm to 7 cm. The 8 mm stent is typically deployed initially, with post-dilation to 10 mm reserved for patients with persistent gradients >12 mmHg. Stent selection depends on hepatic vein and portal vein diameters, with oversizing by 1–2 mm relative to the smaller vessel. For extended tracts, two overlapping stents may be required.[8,11]

Device selection The 10 mm Viatorr stent provides superior hemodynamic decompression but carries higher encephalopathy risk. Consider 8 mm stents in patients with pre-existing encephalopathy, advanced age, or marginal hepatic reserve, with planned upsizing if clinical response is inadequate.

Pressure measurements and endpoints

Portosystemic gradient targets

During the TIPS procedure, the portosystemic pressure gradient (PPG) is calculated as the difference between portal vein pressure and free hepatic vein pressure. Pre-procedure gradients typically exceed 20 mmHg in symptomatic patients. The target post-TIPS PPG is <12 mmHg, which has been validated to significantly reduce rebleeding risk and ascites recurrence.[1,3] Gradients between 12–15 mmHg may be acceptable in patients with high encephalopathy risk, while gradients <5 mmHg increase encephalopathy without additional clinical benefit.

Adjunctive variceal embolization

Despite adequate PPG reduction during the TIPS procedure, gastroesophageal varices may remain perfused via collateral pathways. Concurrent variceal embolization using coils or N-butyl cyanoacrylate (NBCA) during the index TIPS procedure reduces early rebleeding rates. This adjunct is particularly valuable for patients with large gastric varices or a history of recent hemorrhage. Embolization should target the coronary and short gastric veins while preserving splenic venous drainage.[2,3]

Post-procedural care

Immediate recovery and monitoring

After the TIPS procedure, patients are monitored in a step-down or intensive care unit for 12–24 hours. Vital signs, mental status, and abdominal examination are assessed every 2–4 hours. A Doppler ultrasound at 24 hours evaluates stent patency, flow direction, and velocity. TIPS velocities >190 cm/s or <90 cm/s warrant concern for stenosis or thrombosis. Hemoglobin levels are monitored for occult hemorrhage, and electrolytes are checked for procedural contrast effects.[11,16]

Prophylaxis for hepatic encephalopathy

Post-TIPS hepatic encephalopathy develops in 15–30% of patients after the TIPS procedure, with higher rates in those with pre-existing encephalopathy, advanced age, or large-diameter stents. Prophylactic regimens include lactulose titrated to 2–3 soft bowel movements daily and rifaximin 550 mg twice daily for 7–14 days. Protein intake should not be restricted; instead, vegetable protein sources are preferred. Patients and caregivers receive education on encephalopathy recognition, including sleep disturbance, confusion, and asterixis.[16,17]

Recovery protocol Early mobilization is encouraged within 24 hours after the TIPS procedure. Dietary sodium restriction (<2 g/day) and diuretic therapy are continued, with gradual tapering based on clinical response. Patients should avoid nonsteroidal anti-inflammatory drugs and anticoagulants unless specifically indicated for portal vein thrombosis.

Complications and management

Hepatic encephalopathy

New or worsening hepatic encephalopathy represents the most common clinically significant complication of the TIPS procedure, occurring in up to 45% of patients within the first year. Management begins with lactulose optimization and addition of rifaximin. For refractory cases, stent reduction to 8 mm or placement of a constrictor device may restore gradients to 12–15 mmHg while maintaining partial decompression. In extreme cases, shunt occlusion with coils may be necessary, though this risks recurrent portal hypertension complications.[17,18]

Shunt dysfunction and stenosis

Following the TIPS procedure, covered stents maintain 1-year primary patency exceeding 80%, but bare-metal stents develop hemodynamically significant stenosis in 20–30% within 12 months. Surveillance Doppler ultrasound identifies increased velocities (>190 cm/s) or flow reversal as early indicators. TIPS procedure revision involves balloon angioplasty, often with placement of an additional covered stent. Thrombosed TIPS requires mechanical thrombolysis or thrombectomy followed by restenting.[5,9]

Procedure-related hemorrhage

During the TIPS procedure, intraperitoneal hemorrhage from capsular perforation occurs in 1–3% of cases and may require emergent transarterial embolization or laparotomy. Hemobilia from inadvertent biliary puncture typically resolves spontaneously but may require biliary drainage if persistent. Gallbladder puncture is usually benign unless the cystic artery is injured. Meticulous needle technique and limited pass counts minimize these risks.[9,19]

Emergency alert Hemodynamic instability, falling hemoglobin, or peritonitis following the TIPS procedure mandates immediate CT angiography and surgical consultation. Delayed recognition of intraperitoneal hemorrhage carries mortality exceeding 50%.

🔬 Advanced IR Instrumentation

SATSurgical procedure-specific packs provide comprehensive sterile field coverage for complex interventional cases.

Explore SATSurgical →

Follow-up protocols and surveillance

Doppler ultrasound surveillance

After the TIPS procedure, standard surveillance includes Doppler ultrasound at 24 hours, 1 week, 1 month, 3 months, 6 months, and 12 months, then every 6 months thereafter. Key parameters include peak shunt velocity, flow direction, portal vein velocity, and liver parenchymal flow. A peak shunt velocity <90 cm/s or >190 cm/s, absent flow, or hepatofugal portal flow suggests stenosis or thrombosis requiring further evaluation.[11,13]

TIPS procedure revision criteria

Clinical recurrence of ascites, variceal bleeding, or rising PPG on invasive measurement indicates shunt dysfunction after the TIPS procedure. TIPS procedure revision is indicated when Doppler findings suggest stenosis and clinical signs of portal hypertension recur. Revision success rates exceed 90% with balloon angioplasty and additional stent placement. Patients awaiting liver transplantation require coordinated surveillance to ensure TIPS patency is maintained until graft availability.[5,13]

Conclusion

The TIPS procedure represents a cornerstone intervention for managing decompensated portal hypertension. Success depends on meticulous patient selection, precise technical execution with covered stent-grafts, and rigorous post-procedural surveillance. Interventional radiology teams must maintain proficiency in portal vein puncture techniques, pressure-gradient interpretation, and complication management to optimize outcomes. As stent technology evolves and patient selection criteria refine, the TIPS procedure continues to expand its role as both a bridge to transplantation and definitive therapy for select patients with cirrhosis.

🧮 Clinical Decision Support

Access integrated calculators for contrast dosing, hemodynamic assessment, and procedural planning.

Access Clinical Calculators →

SATMED Health Clinical Calculators

🧮 Clinical Calculators for Your Practice

Access integrated decision-support tools designed for interventional radiology and oncology teams.

References

  1. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974. doi:10.1016/j.jhep.2021.12.022
  2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024
  3. Lv Y, Yang Z, Liu B, et al. Early TIPS with covered stent versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis. Lancet Gastroenterol Hepatol. 2019;4(8):587-598. doi:10.1016/S2468-1253(19)30141-1
  4. Bureau C, Adebayo D, Chalret de Rieu M, et al. Alfapump system vs. large volume paracentesis for refractory ascites. J Hepatol. 2017;67(5):940-949. doi:10.1016/j.jhep.2017.06.013
  5. Nicoara-Farcau O, Han G, Rudler M, et al. TIPS in the modern era: A 5-year multicenter retrospective study. JHEP Rep. 2021;3(5):100359. doi:10.1016/j.jhepr.2021.100359
  6. Facciorusso A, Neri V, Gili S, et al. Comparative efficacy of transjugular intrahepatic portosystemic shunt placement for refractory ascites: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(3):446-454. doi:10.1111/jgh.15732
  7. Simonetto DA, Liu M, Gulati R, et al. Baveno VII consensus: The evolving role of TIPS in portal hypertension. Hepatol Int. 2022;16(4):765-774. doi:10.1007/s12072-022-10305-2
  8. Saad WE. Transjugular intrahepatic portosystemic shunt (TIPS) creation: Indications, contraindications, and techniques. Tech Vasc Interv Radiol. 2016;19(1):2-14. doi:10.1053/j.tvir.2016.01.001
  9. Gaba RC, Khiatani VL, Knuttinen MG, et al. Comprehensive review of TIPS technical complications and how to avoid them. AJR Am J Roentgenol. 2018;211(5):1036-1047. doi:10.2214/AJR.18.19847
  10. Fidelman N, Kwan SW, LaBerge JM, et al. The transjugular intrahepatic portosystemic shunt: Update on current techniques and clinical applications. Radiol Clin North Am. 2015;53(5):1041-1056. doi:10.1016/j.rcl.2015.05.009
  11. Dariushnia SR, Haskal ZJ, Midia M, et al. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2016;27(1):1-7. doi:10.1016/j.jvir.2015.09.018
  12. Bettinger D, Sturm L, Pfaff L, et al. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. J Hepatol. 2021;74(5):1132-1142. doi:10.1016/j.jhep.2020.11.019
  13. Casadaban LC, Mina A, Vouche M, et al. TIPS for refractory ascites: A 20-year single-center experience. J Vasc Interv Radiol. 2019;30(11):1723-1731. doi:10.1016/j.jvir.2019.04.026
  14. Praktiknjo M, Book M, Luetkens J, et al. Fat-free muscle mass in cirrhosis predicts post-TIPS outcomes. Liver Int. 2022;42(5):1023-1033. doi:10.1111/liv.15201
  15. Trebicka J, Gu W, Ibáñez-Samaniego L, et al. Rebleeding and mortality following transjugular intrahepatic portosystemic shunt in patients with MELD score ≥ 18. JHEP Rep. 2022;4(2):100421. doi:10.1016/j.jhepr.2022.100421
  16. Intagliata NM, Henry ZH, Shah N, et al. Prophylaxis against hepatic encephalopathy in patients undergoing TIPS: A randomized controlled trial. Hepatology. 2023;77(2):456-467. doi:10.1002/hep.32789
  17. De Gottardi A, Berzigotti A, Seijo S, et al. Post-TIPS refractory hepatic encephalopathy: Current understanding and management. J Hepatol. 2023;78(1):205-218. doi:10.1016/j.jhep.2022.08.030
  18. Rautou PE, Plessier A, Bernuau J, et al. PVT in cirrhosis: Recent advances and clinical management. J Hepatol. 2022;76(5):1165-1178. doi:10.1016/j.jhep.2022.01.008
  19. La Mura V, Nicolini A, Tosetti G, et al. Etiology of portal vein thrombosis and its influence on TIPS outcomes. J Hepatol. 2021;74(5):1085-1093. doi:10.1016/j.jhep.2020.11.028
  20. Sauerbruch T, Mengel M, Dollinger M, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology. 2015;149(3):660-668. doi:10.1053/j.gastro.2015.05.010
  21. Holster IL, Tjwa ET, Moelker A, et al. Covered TIPS versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding. Hepatology. 2016;63(2):579-589. doi:10.1002/hep.28318
  22. Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157-163. doi:10.1053/j.gastro.2016.09.009
  23. Nardelli S, Gioia S, Pasquale C, et al. Cognitive impairment predicts the development of overt hepatic encephalopathy after TIPS. Am J Gastroenterol. 2021;116(3):556-564. doi:10.14309/ajg.0000000000001056
  24. Kimer N, Dahl EK, Gluud LL, Krag A. Anticoagulation in cirrhosis patients with portal vein thrombosis: A systematic review. Liver Int. 2015;35(10):2252-2258. doi:10.1111/liv.12813
  25. Farsad K, Kolbeck KJ. TIPS creation for Budd-Chiari syndrome: Technical considerations and outcomes. Tech Vasc Interv Radiol. 2019;22(3):100-107. doi:10.1053/j.tvir.2019.100107

Subscribe for Updates!